Explain this page
Arphra AIPlain-English read on bioAffinity Technologies, Inc.’s valuation06-16today
- bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells21h
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering4d
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering4d
- bioAffinity Technologies Announces Closing of $3.2 Million Offering4d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.25% | -3.57% | -48.08% | -82.88% | -34.15% | -31.36% | -88.28% | -98.48% | -99.67% | -99.67% | -99.67% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$0.82
Bid
$0.78
66 sh
Ask
$0.87
36 sh
Spread
$0.088
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Real Estate+1.26%
- Industrials+1.00%
- Basic Materials+0.65%
- Energy+0.59%
- Healthcare+0.01%
- Utilities-0.07%
- Financial Services-0.24%
- Communication Services-0.55%
- Technology-0.80%
- Consumer Cyclical-0.85%
- Consumer Defensive-1.00%
Top industries (issuer's industry highlighted)
- Medical - Diagnostics & Research+0.68%
- Biotechnology+6.56%
- Financial - Mortgages-4.05%
- Electrical Equipment & Parts+3.88%
- Staffing & Employment Services-3.62%
- Software - Services-3.30%
- Software - Infrastructure-3.07%
- Advertising Agencies+2.92%
- Apparel - Footwear & Accessories-2.80%
- Engineering & Construction+2.80%
- Financial - Conglomerates+2.62%
- Luxury Goods+2.47%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cellsbusinesswire.com·Jun 22, 2026
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offeringprnewswire.com·Jun 18, 2026
- WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offeringprnewswire.com·Jun 18, 2026
- bioAffinity Technologies Announces Closing of $3.2 Million Offeringbusinesswire.com·Jun 18, 2026
- bioAffinity Technologies Announces Closing of $3.2 Million Offeringbusinesswire.com·Jun 18, 2026
- WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offeringprnewswire.com·Jun 17, 2026
- WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offeringprnewswire.com·Jun 17, 2026
- bioAffinity Technologies Announces Pricing of $3.2 Million Offeringbusinesswire.com·Jun 17, 2026
Peers
No peer list available for BIAF.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|